NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
24 Oct 2018

JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury

JAMA paper to be presented at ESICM conference in Paris.
23 Oct 2018

Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology

Laboratoris Sanifit S.L., today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical Pharmacology.
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure<
18 Oct 2018

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like.
16 Oct 2018

Kala Pharmaceuticals submits new drug application to U.S. Food and Drug Administration for KPI-121 0.25% for dry eye disease

Kala Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%.
03 Oct 2018

Kala Pharmaceuticals announces pricing of public offering of 7,500,000 shares of common stock

Kala Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.25 per share, before offering discounts.
02 Oct 2018

Kala Pharmaceuticals announces financing from Athyrium Capital Management totaling $110 Million

Kala Pharmaceuticals, Inc. today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm.
Minoryx Therapeutics raises €21.3M in Series B funding round<
26 Sep 2018

Minoryx Therapeutics raises €21.3M in Series B funding round

Minoryx Therapeutics, today announces the completion of a Series B funding round of €21.3M.
Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners<
24 Sep 2018

Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners

Ysios Capital has appointed Guillem Laporta as Principal and two new Venture Partners: Lance Berman and Claudia D’Augusta.
18 Sep 2018

BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

BioClin Therapeutics, Inc., today announced the appointment of Scott Myers as Chief Executive Officer, and Julie Eastland as Chief Financial Officer and Chief Business Officer. Mr. Myers will also continue in his role as company Chairman.
05 Sep 2018

Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE)

Minoryx Therapeutics, today announces the dosing of its first US patient as part of its ongoing phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка